MX345227B - Composiciones farmaceuticas solidas que contienen un inhibidor de la integrasa. - Google Patents

Composiciones farmaceuticas solidas que contienen un inhibidor de la integrasa.

Info

Publication number
MX345227B
MX345227B MX2012004903A MX2012004903A MX345227B MX 345227 B MX345227 B MX 345227B MX 2012004903 A MX2012004903 A MX 2012004903A MX 2012004903 A MX2012004903 A MX 2012004903A MX 345227 B MX345227 B MX 345227B
Authority
MX
Mexico
Prior art keywords
tablets
pharmaceutical compositions
compositions containing
solid pharmaceutical
integrase inhibitor
Prior art date
Application number
MX2012004903A
Other languages
English (en)
Other versions
MX2012004903A (es
Inventor
Majid Mahjour
Feng Li
Decheng Ma
Sutthilug Sotthivirat
Original Assignee
Merck Sharp & Dohme Corp *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922462&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX345227(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp * filed Critical Merck Sharp & Dohme Corp *
Publication of MX2012004903A publication Critical patent/MX2012004903A/es
Publication of MX345227B publication Critical patent/MX345227B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a tabletas comprimidas para administración oral que contienen raltegravir en forma de una sal farmacéuticamente aceptable; las tabletas comprenden: (A) un componente intragranular que comprende (i) una cantidad efectiva de una sal de metal alcalino de raltegravir, (u) opcionalmente un primer superdesintegrante, y (iii) un aglutinante; y (B) un componente extragranular el cual comprende (i) un segundo superdesintegrante, (u) un relleno, y (iii) un lubricante; también están descritos métodos para preparar las tabletas y el uso de las tabletas, opcionalmente en combinación con otros agentes anti-VIH, para la inhibición de la integrasa del VIH, para el tratamiento o la profilaxis de la infección por VIH, o para el tratamiento, retraso en la aparición, o la profilaxis del SIDA.
MX2012004903A 2009-10-26 2010-10-21 Composiciones farmaceuticas solidas que contienen un inhibidor de la integrasa. MX345227B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25486909P 2009-10-26 2009-10-26
PCT/US2010/053507 WO2011053504A1 (en) 2009-10-26 2010-10-21 Solid pharmaceutical compositions containing an integrase inhibitor

Publications (2)

Publication Number Publication Date
MX2012004903A MX2012004903A (es) 2012-06-14
MX345227B true MX345227B (es) 2017-01-20

Family

ID=43922462

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004903A MX345227B (es) 2009-10-26 2010-10-21 Composiciones farmaceuticas solidas que contienen un inhibidor de la integrasa.

Country Status (26)

Country Link
US (2) US9649311B2 (es)
EP (2) EP3970702A1 (es)
JP (2) JP6122639B2 (es)
KR (1) KR101835893B1 (es)
CN (2) CN106074411A (es)
AU (1) AU2010313571B2 (es)
BR (1) BR112012009857A8 (es)
CA (1) CA2777937C (es)
CO (1) CO6531485A2 (es)
CY (1) CY1124914T1 (es)
DK (1) DK2493312T3 (es)
ES (1) ES2898348T3 (es)
HR (1) HRP20211826T1 (es)
HU (1) HUE057248T2 (es)
IL (1) IL219369A (es)
IN (1) IN2012DN03377A (es)
LT (1) LT2493312T (es)
MX (1) MX345227B (es)
MY (1) MY162494A (es)
PL (1) PL2493312T3 (es)
PT (1) PT2493312T (es)
RS (1) RS62600B1 (es)
RU (1) RU2602865C2 (es)
SI (1) SI2493312T1 (es)
WO (1) WO2011053504A1 (es)
ZA (1) ZA201203012B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2493312T (pt) 2009-10-26 2021-11-25 Merck Sharp & Dohme Composições farmacêuticas sólidas contendo um inibidor de integrase
JP2014512386A (ja) * 2011-04-22 2014-05-22 メルク・シャープ・アンド・ドーム・コーポレーション 味がマスクされたラルテグラビル製剤
WO2014014933A1 (en) * 2012-07-20 2014-01-23 Merck Sharp & Dohme Corp. Hiv treatment with amido-substituted pyrimidinone derivatives
WO2014064711A2 (en) * 2012-10-22 2014-05-01 Hetero Research Foundation Methods of administering raltegravir and raltegravir compositions
MX364901B (es) * 2012-10-23 2019-05-10 Cipla Ltd Composicion farmaceutica antirretroviral.
EP3019468A4 (en) * 2013-07-11 2017-01-11 Merck Sharp & Dohme Corp. Formulations for cathepsin k inhibitors with vitamin d
CN105237526B (zh) * 2014-06-20 2018-01-23 朱靖华 一种抗艾滋病毒药物及其制备方法
JP7023054B2 (ja) * 2017-04-05 2022-02-21 東和薬品株式会社 レベチラセタム含有医薬組成物及びその製造方法
EP3740209A1 (en) * 2018-01-19 2020-11-25 Gilead Sciences, Inc. Metabolites of bictegravir
US20210290548A1 (en) * 2018-06-06 2021-09-23 Merck Sharp & Dohme Corp. Formulations of raltegravir
RU2688235C1 (ru) * 2018-06-19 2019-05-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" Фармацевтическая противодиабетическая композиция на основе замещенного тиофенкарбоксилата и способ её получения

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9922963D0 (en) 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
DE60036961T2 (de) 1999-11-24 2008-08-28 Merck & Co., Inc. Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1-piperazinpentanamide als hiv-proteasehemmer
CZ20031028A3 (cs) 2000-10-12 2003-08-13 Merck & Co., Inc. Aza- a polyazanaftalenylkarboxamidy
GEP20063848B (en) 2001-10-26 2006-06-12 Inst Di Richerche Di Biolog Moltcolare P Angeletti Spa N-substituted hydroxypyrimi-dinone carboxamide inhibitors of hiv integrase
US7232819B2 (en) 2001-10-26 2007-06-19 Istituto Di Ricerche Di Biologia P. Angeletti S.P.A. Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
EP1499391A2 (en) 2002-04-10 2005-01-26 Merck & Co., Inc. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
US7414045B2 (en) 2002-12-27 2008-08-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Substituted pyrimido[1,2-a]azepines useful as HIV integrase inhibitors
ATE500819T1 (de) 2003-12-31 2011-03-15 Bend Res Inc Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
CA2588466A1 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
NZ555120A (en) * 2004-12-03 2009-11-27 Merck & Co Inc Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition
TR201907729T4 (tr) * 2004-12-03 2019-06-21 Merck Sharp & Dohme Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim.
US20090136570A1 (en) * 2006-01-20 2009-05-28 Bhagwant Rege Taste-Masked Tablets and Granules
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
EP2178511B1 (en) * 2007-06-22 2011-03-02 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
CA2702317A1 (en) * 2007-07-09 2009-01-15 Concert Pharmaceuticals, Inc. Novel pyrimidinecarboxamide derivatives
US8372431B2 (en) * 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
PT2493312T (pt) 2009-10-26 2021-11-25 Merck Sharp & Dohme Composições farmacêuticas sólidas contendo um inibidor de integrase

Also Published As

Publication number Publication date
KR20120102063A (ko) 2012-09-17
RU2012121857A (ru) 2013-12-10
US9649311B2 (en) 2017-05-16
RS62600B1 (sr) 2021-12-31
IL219369A0 (en) 2012-06-28
BR112012009857A8 (pt) 2023-04-11
LT2493312T (lt) 2022-01-10
CN102655752A (zh) 2012-09-05
EP3970702A1 (en) 2022-03-23
CN106074411A (zh) 2016-11-09
HRP20211826T1 (hr) 2022-03-04
ZA201203012B (en) 2012-12-27
HUE057248T2 (hu) 2022-04-28
RU2602865C2 (ru) 2016-11-20
EP2493312A1 (en) 2012-09-05
PT2493312T (pt) 2021-11-25
US20120213851A1 (en) 2012-08-23
DK2493312T3 (da) 2021-12-13
PL2493312T3 (pl) 2022-01-03
CY1124914T1 (el) 2023-01-05
WO2011053504A1 (en) 2011-05-05
US10772888B2 (en) 2020-09-15
KR101835893B1 (ko) 2018-04-19
MY162494A (en) 2017-06-15
AU2010313571B2 (en) 2014-07-31
US20170231993A1 (en) 2017-08-17
AU2010313571A1 (en) 2012-06-07
MX2012004903A (es) 2012-06-14
CO6531485A2 (es) 2012-09-28
IL219369A (en) 2017-06-29
JP6122639B2 (ja) 2017-04-26
BR112012009857A2 (pt) 2015-09-29
CA2777937C (en) 2017-08-29
IN2012DN03377A (es) 2015-10-23
CA2777937A1 (en) 2011-05-05
EP2493312A4 (en) 2013-07-10
SI2493312T1 (sl) 2021-12-31
JP2016034962A (ja) 2016-03-17
ES2898348T3 (es) 2022-03-07
EP2493312B1 (en) 2021-10-20
JP2013508395A (ja) 2013-03-07

Similar Documents

Publication Publication Date Title
MY162494A (en) Solid pharmaceutical compositions containing an integrase inhibitor
WO2005086700A3 (en) Hiv integrase inhibitors
MX2009006285A (es) Inhibidores de transcriptasa inversa no nucleosidicos.
TW200738702A (en) HIV reverse transcriptase inhibitors
MY160000A (en) Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin ii antagonist and/or diuretic
WO2006121831A3 (en) Hiv integrase inhibitors
EA200601654A1 (ru) Ингибиторы интегразы вич
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
WO2010042391A3 (en) Hiv integrase inhibitors
MX2010007083A (es) Combinacion anti-retroviral.
TN2016000230A1 (en) Orally disintegrating solid dosage unit containing an estetrol component.
WO2005110414A3 (en) Hiv integrase inhibitors
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
MX2011005643A (es) Formas de dosificacion oral de bendamustina.
EP2033954A4 (en) COMPOUND 6- (4-OXOQUINOLIN-SUBSTITUTED BENZYL) AND USE THEREOF AS INHIBITOR OF HIV INTEGRASE
WO2007050510A3 (en) Hiv integrase inhibitors
AU2006299042A8 (en) HIV integrase inhibitors
WO2009042094A3 (en) Hiv protease inhibitors
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
MX2020008360A (es) Forma cristalina de bictegravir sodico.
WO2007021629A3 (en) Non-nucleoside reverse transcriptase inhibitors
MX2022002356A (es) Forma de dosificacion oral solida que comprende naproxeno y vitamina b12.
NZ720331A (en) Solid pharmaceutical compositions containing an integrase inhibitor
WO2020013776A3 (en) Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation
RS20050866A (en) Controlled release pharmaceutical composition comprising an acid- insoluble and a bioadhesive polymer

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MERCK SHARP & DOHME CORP.*

HC Change of company name or juridical status

Owner name: MERCK SHARP & DOHME CORP.*

FG Grant or registration